logo

For the Inventor, By the Inventor

Malibu, CA, United States of America

Anthony B Nesburn

This inventor holds 19 USPTO granted patents, primarily in Ophthalmic Treatments. Top assignees: Cedars-Sinai Medical Center, Ista Pharmaceuticals, Inc., Advanced Corneal Systems. Active years: 1991-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Anthony B Nesburn. Retrieved from https://idiyas.com/inventor/anthony-b-nesburn

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19

% Patents Active = 84.2

Average Co-Inventor Count = 4.1

ph-index = 13

Forward Citations = 530(Granted Patents)


Company Filing History:

goldMedal11 out of 628 
 
Cedars-Sinai Medical Center
 patents
silverMedal4 out of 8 
 
Ista Pharmaceuticals, Inc.
 patents
bronzeMedal3 out of 5 
 
Advanced Corneal Systems
 patents
4. 1 out of 16,035 
 
University of California
 patents

Years Active: 1991-2018

Loading Chart...
Areas of Expertise:
Ophthalmic Preparation
Hyaluronidase
Herpes Simplex Virus
Immunogenic Peptides
Vitreous Humor
Cancer Treatment
Glycoproteins
Corneal Hardening
Enzyme Orthokeratology
Amino Acid Polymers
Immunotherapy
Hemorrhagic Clearance
19 patents (USPTO):Explore Patents
1. 9878033 - Immunogenic peptides for treatment of herpes simplex virus infection and conditions (2018-01-30),
2. 6939542 - Hyaluronidase preparation for ophthalmic administration and enzymatic methods for accelerating clearance of hemorrhagic blood from the vitreous body of the eye (2005-09-06),
3. 6863886 - Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders (2005-03-08),
4. 6838279 - Herpes simplex virus type 1 (HSV-1)-derived vector for selectively inhibiting malignant cells and for expressing desired traits in malignant and non-malignant mammalian cells (2005-01-04),
5. 6774119 - HERPES SIMPLEX VIRUS TYPE 1 (HSV-1)-DERIVED VECTOR FOR SELECTIVELY INHIBITING MALIGNANT CELLS AND METHODS FOR ITS USE TO TREAT CANCERS AND TO EXPRESS DESIRED TRAITS IN MALIGNANT AND NON-MALIGNANT MAMMALIAN CELLS (2004-08-10),
6. 6610292 - Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders (2003-08-26),
7. 6551590 - Hyaluronidase preparation for ophthalmic administration and enzymatic methods for accelerating clearance of hemorrhagic blood from the vireous body of the eye (2003-04-22),
8. 6537545 - Use of corneal hardening agents in enzymeorthokeratology (2003-03-25),
9. 6193984 - Pharmaceutical composition of herpes simplex virus typ-1 (HSV-1) glycoproteins (2001-02-27),
10. 6039943 - Method for accelerating clearance of hemorrhagic blood from the vitreous (2000-03-21),
11. 5955088 - Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), (1999-09-21),
12. 5866120 - Method for accelerating clearance of hemorrhagic blood from the vitreous (1999-02-02),
13. 5679348 - Immunotherapy for recurrent HSV infections (1997-10-21),
14. 5672349 - Process for the expression of herpes simplex virus type 1 glycoprotein I (1997-09-30),
15. 5660692 - Method of crosslinking amino acid-containing polymers using (1997-08-26),

Title: **Anthony B. Nesburn: A Pioneer in Immunogenic Compositions and Ophthalmic Solutions**

Introduction

Anthony B. Nesburn, based in Malibu, California, stands out as an influential inventor with a remarkable portfolio of 19 patents. His work primarily revolves around innovative medical solutions, particularly aimed at treating viral infections and enhancing ophthalmic procedures.

Latest Patents

Among his most recent innovations is the patent for immunogenic peptides designed for the treatment of herpes simplex virus infections. This invention provides immunogenic compositions that include peptides with specific amino acid sequences, which are crucial for inducing protective immunity against HSV-1 and HSV-2 infections. Another notable contribution from Nesburn is his patent for a hyaluronidase preparation intended for ophthalmic administration. This preparation is designed to effectively accelerate the clearance of hemorrhagic blood from the vitreous body of the eye using various enzymes, improving patient outcomes significantly.

Career Highlights

Throughout his distinguished career, Anthony B. Nesburn has worked with prominent institutions, including Cedars-Sinai Medical Center and Ista Pharmaceuticals, Inc. His contributions to these organizations have been vital in advancing medical research and the development of therapeutic solutions.

Collaborations

Nesburn's journey has included collaborations with esteemed coworkers such as Vicken H. Karageozian and Steven L. Wechsler. Together, they have contributed to groundbreaking research and innovative medical applications, further establishing their reputations in the industry.

Conclusion

Anthony B. Nesburn exemplifies the spirit of innovation in the medical field. His patents reflect a commitment to addressing complex health challenges and enhancing treatment methodologies. With a focus on developing immunogenic compositions and unique ophthalmic solutions, Nesburn continues to influence the landscape of medical science through his inventive spirit and dedication to research.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…